Literature DB >> 19125886

Tricks with tetramers: how to get the most from multimeric peptide-MHC.

Linda Wooldridge1, Anna Lissina, David K Cole, Hugo A van den Berg, David A Price, Andrew K Sewell.   

Abstract

The development of fluorochrome-conjugated peptide-major histocompatibility complex (pMHC) multimers in conjunction with continuing advances in flow cytometry has transformed the study of antigen-specific T cells by enabling their visualization, enumeration, phenotypic characterization and isolation from ex vivo samples. Here, we bring together and discuss some of the 'tricks' that can be used to get the most out of pMHC multimers. These include: (1) simple procedures that can substantially enhance the staining intensity of cognate T cells with pMHC multimers; (2) the use of pMHC multimers to stain T cells with very-low-affinity T-cell receptor (TCR)/pMHC interactions, such as those that typically predominate in tumour-specific responses; and (3) the physical grading and clonotypic dissection of antigen-specific T cells based on the affinity of their cognate TCR using mutant pMHC multimers in conjunction with new approaches to the molecular analysis of TCR gene expression. We also examine how soluble pMHC can be used to examine T-cell activation, manipulate T-cell responses and study allogeneic and superantigen interactions with TCRs. Finally, we discuss the problems that arise with pMHC class II (pMHCII) multimers because of the low affinity of TCR/pMHCII interactions and lack of 'coreceptor help'.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19125886      PMCID: PMC2632693          DOI: 10.1111/j.1365-2567.2008.02848.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  116 in total

Review 1.  Class II major histocompatibility complex tetramer staining: progress, problems, and prospects.

Authors:  Sabrina S Vollers; Lawrence J Stern
Journal:  Immunology       Date:  2008-03       Impact factor: 7.397

Review 2.  T-cell receptor bias and immunity.

Authors:  Stephanie Gras; Lars Kjer-Nielsen; Scott R Burrows; James McCluskey; Jamie Rossjohn
Journal:  Curr Opin Immunol       Date:  2008-01-18       Impact factor: 7.486

3.  Dose-dependent modulation of CD8 and functional avidity as a result of peptide encounter.

Authors:  Charles J Kroger; Martha A Alexander-Miller
Journal:  Immunology       Date:  2007-05-02       Impact factor: 7.397

4.  Kinetics of MHC-CD8 interaction at the T cell membrane.

Authors:  Jun Huang; Lindsay J Edwards; Brian D Evavold; Cheng Zhu
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

5.  T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.

Authors:  Matthias T Stephan; Vladimir Ponomarev; Renier J Brentjens; Alex H Chang; Konstantin V Dobrenkov; Glenn Heller; Michel Sadelain
Journal:  Nat Med       Date:  2007-11-18       Impact factor: 53.440

6.  Coreceptor CD8-driven modulation of T cell antigen receptor specificity.

Authors:  Hugo A van den Berg; Linda Wooldridge; Bruno Laugel; Andrew K Sewell
Journal:  J Theor Biol       Date:  2007-08-08       Impact factor: 2.691

7.  Use of peptide-major histocompatibility complex tetramer technology to study interactions between Staphylococcus aureus proteins and human cells.

Authors:  Ruth C Massey; Thomas J Scriba; Eric L Brown; Rodney E Phillips; Andrew K Sewell
Journal:  Infect Immun       Date:  2007-10-15       Impact factor: 3.441

8.  'Coreceptor tuning': cytokine signals transcriptionally tailor CD8 coreceptor expression to the self-specificity of the TCR.

Authors:  Jung-Hyun Park; Stanley Adoro; Philip J Lucas; Sophia D Sarafova; Amala S Alag; Loretta L Doan; Batu Erman; Xiaolong Liu; Wilfried Ellmeier; Remy Bosselut; Lionel Feigenbaum; Alfred Singer
Journal:  Nat Immunol       Date:  2007-09-16       Impact factor: 25.606

9.  Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties.

Authors:  Bruno Laugel; Hugo A van den Berg; Emma Gostick; David K Cole; Linda Wooldridge; Jonathan Boulter; Anita Milicic; David A Price; Andrew K Sewell
Journal:  J Biol Chem       Date:  2007-05-31       Impact factor: 5.157

10.  The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor.

Authors:  Marco A Purbhoo; Yi Li; Deborah H Sutton; Joanna E Brewer; Emma Gostick; Giovanna Bossi; Bruno Laugel; Ruth Moysey; Emma Baston; Nathaniel Liddy; Brian Cameron; Alan D Bennett; Rebecca Ashfield; Anita Milicic; David A Price; Brendan J Classon; Andrew K Sewell; Bent K Jakobsen
Journal:  Mol Cancer Ther       Date:  2007-07       Impact factor: 6.261

View more
  87 in total

Review 1.  Properties and applications of single-chain major histocompatibility complex class I molecules.

Authors:  Eleni Kotsiou; Joanna Brzostek; Keith G Gould
Journal:  Antioxid Redox Signal       Date:  2011-03-31       Impact factor: 8.401

2.  Persistent viral infection in humans can drive high frequency low-affinity T-cell expansions.

Authors:  Naeem Khan; Mark Cobbold; Joanne Cummerson; Paul A H Moss
Journal:  Immunology       Date:  2010-08-16       Impact factor: 7.397

3.  T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.

Authors:  Elaine M Sloand; J Joseph Melenhorst; Zachary C G Tucker; Loretta Pfannes; Jason M Brenchley; Agnes Yong; Valeria Visconte; Colin Wu; Emma Gostick; Phillip Scheinberg; Matthew J Olnes; Daniel C Douek; David A Price; A John Barrett; Neal S Young
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

4.  A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis.

Authors:  Adam M Swartz; Elizabeth Reap; Pamela Norberg; Robert Schmittling; Sylvia Janetzki; Luis Sanchez-Perez; John H Sampson
Journal:  J Immunol Methods       Date:  2018-05-31       Impact factor: 2.303

5.  Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research.

Authors:  Philippe Guillaume; Danijel Dojcinovic; Immanuel F Luescher
Journal:  Cancer Immun       Date:  2009-09-25

Review 6.  Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.

Authors:  Joseph J Sabatino; Kristen M Rosenthal; Brian D Evavold
Journal:  J Neuroimmune Pharmacol       Date:  2009-11-11       Impact factor: 4.147

7.  Escape from highly effective public CD8+ T-cell clonotypes by HIV.

Authors:  Maria Candela Iglesias; Jorge R Almeida; Solène Fastenackels; David J van Bockel; Masao Hashimoto; Vanessa Venturi; Emma Gostick; Alejandra Urrutia; Linda Wooldridge; Mathew Clement; Stéphanie Gras; Pascal G Wilmann; Brigitte Autran; Arnaud Moris; Jamie Rossjohn; Miles P Davenport; Masafumi Takiguchi; Christian Brander; Daniel C Douek; Anthony D Kelleher; David A Price; Victor Appay
Journal:  Blood       Date:  2011-07-06       Impact factor: 22.113

Review 8.  T cell antigen discovery.

Authors:  Alok V Joglekar; Guideng Li
Journal:  Nat Methods       Date:  2020-07-06       Impact factor: 28.547

9.  Development of an epitope panel for consistent identification of antigen-specific T-cells in humans.

Authors:  Andreas Fløe; Caroline Løppke; Ole Hilberg; Christian Wejse; Liselotte Brix; Kivin Jacobsen
Journal:  Immunology       Date:  2017-07-03       Impact factor: 7.397

10.  Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses.

Authors:  Yun Lin; Humilidad F Gallardo; Geoffrey Y Ku; Hao Li; Gregor Manukian; Teresa S Rasalan; Yinyan Xu; Stephanie L Terzulli; Lloyd J Old; James P Allison; Alan N Houghton; Jedd D Wolchok; Jianda Yuan
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.